Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma: treatments, trials & survival

Non-Hodgkin lymphoma includes many subtypes of blood cancer. Explore treatments including CAR-T therapy, immunotherapy, and ongoing clinical trials.

New Cases (2024)
80,620
5-Yr Survival
74.3%
Annual Deaths
20,140
Trend
Stable
See active trials

About Non-Hodgkin Lymphoma

Non-Hodgkin lymphoma includes many subtypes of blood cancer. Explore treatments including CAR-T therapy, immunotherapy, and ongoing clinical trials.

According to the National Cancer Institute’s SEER database, an estimated 80,620 new cases of non-hodgkin lymphoma will be diagnosed in the United States in 2024, with approximately 20,140 deaths. The overall 5-year relative survival rate is 74.3%.

Source: NCI SEER Data: 1975–2022

Treatment options

Current treatment approaches for non-hodgkin lymphoma depend on the stage at diagnosis, tumor characteristics, and the patient’s overall health. The most common options include:

1
Chemotherapy (R-CHOP)
2
Immunotherapy (Rituximab)
3
CAR-T Cell Therapy
4
Radiation Therapy
5
Stem Cell Transplant
6
Targeted Therapy (Ibrutinib, Venetoclax)

Treatment recommendations should always be discussed with a qualified oncologist. The options listed above are based on current clinical guidelines and may vary case by case.

Stages

Staging describes the extent of cancer in the body and is crucial for planning the most appropriate treatment:

Stage I Stage II Stage III Stage IV

Known risk factors

Understanding risk factors can support prevention and early detection. Known risk factors for this cancer include:

Weakened immune system
Autoimmune diseases
Infections (EBV, H. pylori)
Chemical exposure
Age
Family history

Not sure where to start?

A patient navigator familiar with non-hodgkin lymphoma can help you understand your options and connect you with top US hospitals. Free & confidential.

Active clinical trials

Clinical trials offer access to cutting-edge treatments not yet widely available. The trials below are sourced in real time from ClinicalTrials.gov:

Frequently asked questions

The 5-year relative survival rate for NHL is 74.3%. Survival varies widely by subtype, from highly curable types like diffuse large B-cell lymphoma to more indolent forms.
R-CHOP is the standard chemotherapy regimen combining Rituximab with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. It is the first-line treatment for many NHL subtypes.
CAR-T therapy uses genetically modified patient T-cells to target CD19 on lymphoma cells. Products like axicabtagene ciloleucel and tisagenlecleucel are approved for relapsed/refractory large B-cell lymphoma.
The key difference is the presence of Reed-Sternberg cells in Hodgkin lymphoma. NHL is more common, has more subtypes, and tends to occur in older adults, while Hodgkin lymphoma typically affects younger people.
You’re not alone

Looking for non-hodgkin lymphoma treatment options?

A patient navigator can help you explore treatment pathways, find clinical trials near you, and connect with specialists who see non-hodgkin lymphoma every day. Free, confidential consultation.

Send a message
Free callback

Talk to a navigator

Leave your details and we’ll call you at your preferred time.